Rodent Resistance to the Anticoagulant Rodenticides, with Particular Reference to Denmark
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Occurrence, Elimination, and Risk of Anticoagulant Rodenticides in Wastewater and Sludge
Occurrence, elimination, and risk of anticoagulant rodenticides in wastewater and sludge Silvia Lacorte, Cristian Gómez- Canela Department of Environmental Chemistry, IDAEA-CSIC, Jordi Girona 18-26, 08034 Barcelona Rats and super-rats Neverending story 1967 Coumachlor 1 tn rodenticides /city per campaign “It will be the LAST ONE” Rodenticides Biocides: use regulated according to EU. Used mainly as bait formulations. First generation: multiple feedings, less persistent in tissues, commensal and outdoor use. Second generation: single feeding (more toxic), more persistent in tissue, commensal use only. Toxic: vitamin K antagonists that cause mortality by blocking an animal’s ability to produce several key blood clotting factors. High oral, dermal and inhalation toxicity. Origin and fate of rodenticides Study site: Catalonia (7.5 M inhabitants) 1693 km of sewage corridor 13 fluvial tanks (70.000 m3) 130,000,000 € / 8 YEARS 32,000 km2 378,742 kg/y AI 2,077,000 € Objectives 1. To develop an analytical method to determine most widely used rodenticides in wastewater and sludge. 2. To monitor the presence of rodenticides within 9 WWTP receiving urban and agricultural waters. 3. To evaluate the risk of rodenticides using Daphnia magna as aquatic toxicological model. 4. To study the accumulation of rodenticides in sludge. Compounds studied Coumachlor* Pindone C19H15ClO4 C14H14O3 Dicoumarol Warfarin C19H12O6 C19H16O4 Coumatetralyl Ferulenol FGARs C19H16O3 C24H30O3 Acenocoumarol Chlorophacinone • Solubility C19H15NO6 C23H15ClO3 0.001-128 mg/L • pKa 3.4-6.6 Flocoumafen Bromadiolone C H F O C H BrO 33 25 3 40 30 23 4 • Log P 1.92-8.5 Brodifacoum Fluindione C H BrO 31 23 3 C15H9FO2 SGARs Difenacoum Fenindione C31H24O3 C15H10O2 1. -
Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-Target Organisms Katherine Horak U.S
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln USDA National Wildlife Research Center - Staff U.S. Department of Agriculture: Animal and Plant Publications Health Inspection Service 2018 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine Horak U.S. Department of Agriculture, [email protected] Penny M. Fisher Landcare Research Brian M. Hopkins Landcare Research Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc Part of the Life Sciences Commons Horak, Katherine; Fisher, Penny M.; and Hopkins, Brian M., "Pharmacokinetics of Anticoagulant Rodenticides in Target and Non- target Organisms" (2018). USDA National Wildlife Research Center - Staff Publications. 2091. https://digitalcommons.unl.edu/icwdm_usdanwrc/2091 This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff ubP lications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Chapter 4 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine E. Horak, Penny M. Fisher, and Brian Hopkins 1 Introduction The concentration of a compound at the site of action is a determinant of its toxicity. This principle is affected by a variety of factors including the chemical properties of the compound (pKa, lipophilicity, molecular size), receptor binding affinity, route of exposure, and physiological properties of the organism. Many compounds have to undergo chemical changes, biotransformation, into more toxic or less toxic forms. Because of all of these variables, predicting toxic effects and performing risk assess- ments of compounds based solely on dose are less accurate than those that include data on absorption, distribution, metabolism (biotransformation), and excretion of the compound. -
New Zealand Data Sheet 1
New Zealand Data Sheet 1. PRODUCT NAME NAXEN® 250 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each NAXEN 250 mg tablet contains 250 mg of Naproxen For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM NAXEN 250 mg tablets are yellow, biconvex, round tablet of 11 mm diameter with one face engraved NX250 and having a bisecting score. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications NAXEN is indicated in adults for the relief of symptoms associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis and bursitis, acute gout and primary dysmenorrhoea. NAXEN is indicated in children for juvenile arthritis. 4.2. Dose and method of administration After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used (see Section 4.4). During long-term administration the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. In patients who tolerate lower doses well, the dose may be increased to 1000 mg per day when a higher level of anti-inflammatory/analgesic 1 | P a g e activity is required. When treating patients with naproxen 1000 mg/day, the physician should observe sufficient increased clinical benefit to offset the potential increased risk. Dose Adults For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis Initial therapy: The usual dose is 500-1000 mg per day taken in two doses at 12 hour intervals. -
RRAC Guidelines on Anticoagulant Rodenticide Resistance Management Editor: Rodenticide Resistance Action Committee (RRAC) of Croplife International Aim
RRAC guidelines on Anticoagulant Rodenticide Resistance Management Editor: Rodenticide Resistance Action Committee (RRAC) of CropLife International Aim This document provides guidance to advisors, national authorities, professionals, practitioners and others on the nature of anticoagulant resistance in rodents, the identification of anticoagulant resistance, strategies for rodenticide application that will avoid the development of resistance and the management of resistance where it occurs. The Rodenticide Resistance Action Committee (RRAC) is a working group within the framework of CropLife International. Participating companies include: Bayer CropScience, BASF, LiphaTech S. A., PelGar, Rentokil Initial, Syngenta and Zapi. Senior technical specialists, with specific expertise in rodenticides, represent their companies on this committee. The RRAC is grateful to the following co-authors: Stefan Endepols, Alan Buckle, Charlie Eason, Hans-Joachim Pelz, Adrian Meyer, Philippe Berny, Kristof Baert and Colin Prescott. Photos provided by Stefan Endepols. Contents 1. Introduction ............................................................................................................................................................................................................. 2 2. Classification and history of rodenticide compounds ..............................................................................................3 3. Mode of action of anticoagulant rodenticides, resistance mechanisms, and resistance mutations ......................................................................................................6 -
Perioperative Management of Patients Treated with Antithrombotics in Oral Surgery
SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 SOCIÉTÉ FRANÇAISE DE CHIRURGIE ORALE [FRENCH SOCIETY OF ORAL SURGERY] IN COLLABORATION WITH THE SOCIÉTÉ FRANÇAISE DE CARDIOLOGIE [FRENCH SOCIETY OF CARDIOLOGY] AND THE PERIOPERATIVE HEMOSTASIS INTEREST GROUP Space Perioperative management of patients treated with antithrombotics in oral surgery. RATIONALE July 2015 P a g e 1 | 107 SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 Abbreviations ACS Acute coronary syndrome(s) ADP Adenosine diphosphate Afib Atrial Fibrillation AHT Arterial hypertension Anaes Agence nationale d’accréditation et d’évaluation en santé [National Agency for Accreditation and Health Care Evaluation] APA Antiplatelet agent(s) aPTT Activated partial thromboplastin time ASA Aspirin BDMP Blood derived medicinal products BMI Body mass index BT Bleeding Time cAMP Cyclic adenosine monophosphate COX-1 Cyclooxygenase 1 CVA Cerebral vascular accident DIC Disseminated intravascular coagulation DOA Direct oral anticoagulant(s) DVT Deep vein thrombosis GEHT Study Group on Hemostasis and Thrombosis (groupe d’étude sur l’hémostase et la thrombose) GIHP Hemostasis and Thrombosis Interest Group (groupe d’intérêt sur l’hémostase et la thrombose) HAS Haute autorité de santé [French Authority for Health] HIT Heparin-induced thrombocytopenia IANB Inferior alveolar nerve block INR International normalized ratio IV Intravenous LMWH Low-molecular-weight heparin(s) -
Hazardous Materials List
Hazardous Materials List Version: 1.12.2016 v 1.4 All agrochemicals, especially pesticides, can be potentially hazardous in some form or other to human and animal health as well as to the environment and therefore should be used only under caution. Fairtrade International recommends the use of other methods like proper choice of crops and varieties, suitable cultivation practices and biological material for pest, before a chemical pesticide is used for pest control. The Hazardous Materials List (HML) is divided in three lists: the Red List, the Orange List and the Yellow List. Red List: The Red List is a ‘prohibited’ list and includes materials that must not be used on Fairtrade products. Orange List: The Orange List is a ‘restricted’ List and includes materials that may be used under conditions specified in this document thus restricting their use. The use of materials in this list will be monitored by Fairtrade International. Operators should be aware that some of these materials are to be phased out by 30 June 2020 or by 30 June 2022 as indicated in the list. The other materials in the list may eventually be prohibited and are encouraged to abandon their use. Yellow List: The Yellow List is a ‘flagged’ list and includes materials which are flagged for being hazardous and should be used under extreme caution. Fairtrade International will be monitoring the classification of these materials by international bodies like PAN, WHO and FAO, and materials may be prohibited in the future. Operators are encouraged to abandon their use. Classification of materials in the HML The Hazardous Materials List includes materials that are identified as Highly Hazardous as defined in the Code of Conduct on Pesticide Management adopted by FAO and WHO in 2013. -
Drug Interactions and Lethal Drug Combinations
J Clin Pathol: first published as 10.1136/jcp.28.Suppl_9.94 on 1 January 1975. Downloaded from J. clin. Path., 28, Suppl. (Roy. Coll. Path.), 9, 94-98 The drug dilemma-benefits and hazards Drug interactions and lethal drug combinations ALAN RICHENS From the Department of Clinical Pharmacology, St Bartholomew's Hospital, London Although the development of drugs of greater example, aspirin can displace oral anticoagulants potency and efficacy confers on the physician from their plasma-protein-binding sites, and in- increasing power to treat serious diseases, it also directly acting sympathomimetics contained in cough increases the number and seriousness of potential mixtures can cause a hypertensive crisis in patients adverse effects and drug interactions which can on monoamine oxidase inhibitors. Self-medication is occur. Most hospital patients receive more than one common, and often involves drugs obtained on drug at a time, the average number often being prescription for a previous illness. greater than five (Smith, Seidl, and Cluff, 1966). The 4 When several clinics or doctors are involved in incidence of drug reactions rises with the number of the care of a patient, one doctor may not be aware of drugs prescribed simultaneously. In patients pre- what another has prescribed. scribed one to five drugs the incidence of reactions is 5 When preparations which contain more than 18-6%, while in patients prescribed six or more one ingredient are prescribed by their trade names. it rises to 814 % (Hurwitz and Wade, 1969). There are a number of ways in which drugs may The Boston Collaborative Drug Surveillance interact. -
First-Generation Anticoagulants
• First-Generation Anticoagulants and Non-Anticoagulants: Warfarin, Diphacinone, Chlorophacinone, Zinc Phosphide, Bromethalin, Cholecalciferol • Second-Generation Anticoagulants: Brodifacoum, Difethialone, Bromadiolone, Difenacoum LETHAL DOSE CHART: PET SECONDARY POISONING CHART TIER 1 BAIT STATIONS BELL LABS CERTIFIES THAT ITS PROTECTA EVO EXPRESS MEETS TIER 1 BAIT STATION STANDARDS Protecta EVO Express passed all requirements necessary to certify Tier 1 bait station. • It must pass EPA established protocols that demonstrate resistance to both children and dogs, as well as, performance features for weather resistance. The Protecta EVO Express is Child Resistant: EPA protocol 1.229 • tested with at least 50 children to ensure they are unable to open the station or reach inside and access the placebo bait. The Protecta EVO Express passed this test with 50 out of 50 children unable to open station or access the placebo bait. TIER 1 BAIT STATIONS The Protecta EVO Express is Dog Resistant:. EPA protocol 1.230 • requires that 6 dogs greater than 40 lbs are denied access to the bait for up to 2 hours ***Bell felt that this protocol would (and perhaps has) allowed some companies to “game” the test by choosing “passive dogs”, thus achieving a “pass” without ever actually challenging the integrity of the station Bell worked with EPA to design a more rigorous test. Bell’s EPA approved protocol • requires 12 dogs to actively interact within the first 15 minutes of exposure or the dog is disqualified. • Express passed all 12 dogs without a single failure PROTECTA EVO EXPRESS Tier 1 Certified . -
Prohibited and Restricted Pesticides List Fair Trade USA® Agricultural Production Standard Version 1.1.0
Version 1.1.0 Prohibited and Restricted Pesticides List Fair Trade USA® Agricultural Production Standard Version 1.1.0 Introduction Through the implementation of our standards, Fair Trade USA aims to promote sustainable livelihoods and safe working conditions, protection of the environment, and strong, transparent supply chains.. Our standards work to limit negative impacts on communities and the environment. All pesticides can be potentially hazardous to human health and the environment, both on the farm and in the community. They can negatively affect the long-term sustainability of agricultural livelihoods. The Fair Trade USA Agricultural Production Standard (APS) seeks to minimize these risks from pesticides by restricting the use of highly hazardous pesticides and enhancing the implementation of risk mitigation practices for lower risk pesticides. This approach allows greater flexibility for producers, while balancing controls on impacts to human and environmental health. This document lists the pesticides that are prohibited or restricted in the production of Fair Trade CertifiedTM products, as required in Objective 4.4.2 of the APS. It also includes additional rules for the use of restricted pesticides. Purpose The purpose of this document is to outline the rules which prohibit or restrict the use of hazardous pesticides in the production of Fair Trade Certified agricultural products. Scope • The Prohibited and Restricted Pesticides List (PRPL) applies to all crops certified against the Fair Trade USA Agricultural Production Standard (APS). • Restrictions outlined in this list apply to active ingredients in any pesticide used by parties included in the scope of the Certificate while handling Fair Trade Certified products. -
Recommended Classification of Pesticides by Hazard and Guidelines to Classification 2019 Theinternational Programme on Chemical Safety (IPCS) Was Established in 1980
The WHO Recommended Classi cation of Pesticides by Hazard and Guidelines to Classi cation 2019 cation Hazard of Pesticides by and Guidelines to Classi The WHO Recommended Classi The WHO Recommended Classi cation of Pesticides by Hazard and Guidelines to Classi cation 2019 The WHO Recommended Classification of Pesticides by Hazard and Guidelines to Classification 2019 TheInternational Programme on Chemical Safety (IPCS) was established in 1980. The overall objectives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations. The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase international coordination in the field of chemical safety. The Participating Organizations are: FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment. WHO recommended classification of pesticides by hazard and guidelines to classification, 2019 edition ISBN 978-92-4-000566-2 (electronic version) ISBN 978-92-4-000567-9 (print version) ISSN 1684-1042 © World Health Organization 2020 Some rights reserved. -
Dicoumarol: a Unique Microtubule Stabilizing Natural Product That Is Synergistic with Taxol1
[CANCER RESEARCH 63, 1214–1220, March 15, 2003] Dicoumarol: A Unique Microtubule Stabilizing Natural Product that Is Synergistic with Taxol1 Hamta Madari, Dulal Panda, Leslie Wilson, and Robert S. Jacobs2 Departments of Ecology, Evolution, and Marine Biology [H. M., R. S. J.] and Molecular, Cellular, and Developmental Biology [L. W.], University of California, Santa Barbara, California 93106, and Bhupat and Jyoti Mehta School of Biosciences and Bioengineering, Indian Institute of Technology, Bombay, Mumbai, India 400076 [D. P.] ABSTRACT prostate cancer, malignant melanoma, and metastatic renal cell carci- noma (12–14). In studies on the antiproliferative actions of coumarin compounds, we In addition, the coumarin anticoagulants, dicoumarol (Dicumarol) -discovered that dicoumarol (a coumarin anticoagulant; 3,3-methyl and its synthetic derivative warfarin sodium (Coumadin), have been enebis[4-hydroxycoumarin]) inhibits the first cleavage of Strongylocentro- tus purpuratus (sea urchin) embryos in a concentration-dependent manner shown to decrease metastases in experimental animals (15). Warfarin with 50% inhibition occurring at a concentration of 10 M. Because first sodium, largely replacing dicoumarol therapeutically as an anticoag- cleavage in sea urchin embryos is highly selective for microtubule- ulant, has been used for the treatment of a variety of cancers and targeted agents, we thought that the active compounds might inhibit cell shown to improve tumor response rates and survival in patients with division by interacting with tubulin or microtubules. We found that several types of cancer (16–22). However, despite numerous studies, dicoumarol binds to bovine brain tubulin with a Kd of 22 M and that 0.1 little information has been acquired on the cellular mechanism of M dicoumarol strongly stabilizes the growing and shortening dynamics action of coumarin compounds in the treatment of malignancies. -
Some Aspects of the Pharmacology of Oral Anticoagulants
Some aspects of the pharmacology of oral anticoagulants The pharmacology of oral anticoagulants ls discussed with particular rejerence to data of value in the management of therapy. The importance of individual variability in response and drug interaction is stressed. Other effects of these agents which may have clinical utility are noted. William W. Coon, M.D., and Park W. Willis 111, M.D., Ann Arbor, Mich. The Departments of Surgery (Section of General Surgery) and Medicine, University of Michigan Medical School In the twenty-five years sinee the isola dividual struetural features but by a com tion of the hemorrhagie faetor in spoiled bination of several: molecular shape, in sweet clever," the gradually inereasing creased aetivity with 6 membered hetero utilization of oral antieoagulants for the eyclic rings with a substituent in position prevention and therapy of thromboembolie 8 and with a methoxyl rather than a free disease has made them one of the most hydroxl group. Also important is the dernon widely used groups of pharmacologic stration that levorotatory warfarin is seven agents. This review is restrieted to as times more aetive than its enantiomer.F" peets of the pharmaeology of these agents As Hunter and Shepherd'" have pointed whieh may be important to their proper out, the failure to obtain a precise cor clinieal utilization. relation between strueture and antieoagu lant aetivity is "not surprising in view of Relation of structure to function the influence of small struetural changes The oral antieoagulants have been di on sueh variables as solubility, rate of ab vided into four main groups on the basis sorption, ease of distribution, degree of of ehemieal strueture (Fig.